Log in


We are delighted to announce that Professor Guy Goodwin, Emeritus Professor at the University of Oxford, will deliver a keynote lecture at CINP 2026.

His presentation, “Remedicalising Psychedelic Drugs for Psychiatry,” will explore the implications of his latest groundbreaking research and discuss the recently released findings that are helping to shape the future of psychedelic medicine in psychiatry.

This keynote promises to provide valuable insights into one of the most exciting and rapidly evolving areas of contemporary psychiatric research.

Mark your diary not to miss it:
Monday, June 29, at 9:10 am

Check the full scientific program and start planning, which sessions are on your must-see list!

View CINP2026 Program




We are pleased to congratulate the newly elected officers and councillors, who will officially assume their roles during the CINP 2026 Congress.

  • President Elect 2026–2028
    Gregers Wegener
  • Vice-President 2026–2030
    Ming-Chyi Huang
  • Treasurer 2026–2030
    Lucie Bartova
  • Councillors 2026–2030
    Hilary Blumberg
    Kim Q. Do
    Cheng-Ta Li
    Julio Licinio
    Atsumi Nitta

We warmly congratulate all those elected and look forward to their leadership and contributions to the global CINP community in the years ahead.

We would also like to sincerely thank all candidates who stood in this election for their commitment, engagement, and willingness to serve CINP and the field of neuropsychopharmacology.

Wiew New Officers' Profiles


Planning your trip to Glasgow for CINP 2026?

We would encourage you to arrange your accommodation as early as possible. The city will be particularly busy during the congress dates, with several major concerts and events taking place at the same time, and hotel availability is already becoming limited.

We look forward to welcoming our community to Glasgow and want to ensure your stay is as smooth and comfortable as possible.

You are welcome to check the available rooms on the congress website. 

Book early to secure your preferred option!


Book Now



Follow CINP on Social Media

Stay connected with the latest news, research highlights, events, and updates from CINP.

Join our growing global community across social media:

Facebook:
https://www.facebook.com/cinp.org

X (Twitter):
https://x.com/theCINP

Instagram: 
https://www.instagram.com/cinporg

LinkedIn: https://www.linkedin.com/company/international-college-of-neuropsychopharmacology/

YouTube:
https://www.youtube.com/@cinp1422

Follow us to stay informed, engage with the community, and be part of the conversation shaping the future of neuropsychopharmacology.


We are excited to announce the recipients of the Rafaelsen Young Investigators Award 2026:

  • Benson Ku, USA
  • Martin Osugo, UK
  • Anjali Sankar, Denmark

Due to a very high number of entries of exceptional quality, the following applicants have been awarded a President's Recognition for Young Investigators diploma:

  • Shokouh Arjmand, Denmark
  • Dibyadeep Datta, USA
  • Vivian Marcela Garzon Rubiano, Colombia
  • Martha Lopez-Canul, Canada
  • Chiara Montemitro, Italy
  • Devon Stoliker, Australia
  • Biju Viswanath, India

Congratulations to all awardees!

All Details About Awards


We are pleased to share a new Genomic Press Interview with Dr. Gabriella Gobbi, CINP President Elect, Professor of Psychiatry at McGill University, and Canada Research Chair in Therapeutics for Mental Health.

From pioneering research on adolescent cannabis exposure and depression, to advancing novel melatonin receptor therapeutics, and early work on the neurobiology of psychedelics - Dr. Gobbi’s career exemplifies truly translational science.

As the first woman elected CINP President in its 70-year history, she reflects on her journey from Italy to Canada, the clinical insights that shaped her research, and her vision for a neuropsychopharmacology that remains deeply connected to patient care.

Read the full interview


GLOBAL
Guidelines

Read the various treatment guidelines  written by CINP Members and endorsed by CINP.


International Journal of Neuropsychopharmacology

Impact Factor: 3.7